Liver cancer is the fifth most common cancer and the second leading cause of malignant
death in Asia, and Asia reports 72.5% of the world's cases in 2020. As the most common …

The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

The growing knowledge of ferroptosis has suggested the role and therapeutic potential of
ferroptosis in cancer, but has not been translated into effective therapy. Liver cancer …

Hepatocellular carcinoma (HCC) arises from hepatocytes through the sequential
accumulation of multiple genomic and epigenomic alterations resulting from Darwinian …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

Objective Infection by HBV is the main risk factor for hepatocellular carcinoma (HCC)
worldwide. HBV directly drives carcinogenesis through integrations in the human genome …

The poor outcome of patients with non-surgically removable advanced hepatocellular
carcinoma (HCC), the most frequent type of primary liver cancer, is mainly due to the high …

Hepatocellular carcinoma (HCC) comprises approximately 80% of primary liver cancer.
HCC is the only major cancer for which death rates have not improved over the last ten …

Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …

Cancer cells voraciously consume nutrients to support their growth, exposing metabolic
vulnerabilities that can be therapeutically exploited. Here, we show in hepatocellular …